GlassScriptPhysician profile
Eisha Mubashir
NPI 1629036884
$6,494.12
in general payments reported to CMS, 2019-2025
26 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $244 · 2021: $764 · 2022: $1,045 · 2023: $1,279 · 2024: $1,205 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.33 |
| Education | $130.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,269.72 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $976.17 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $901.65 | 2019-2025 | |
| Pfizer INC. | $596.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $435.74 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $407.38 | 2019-2025 | |
| Ucb, INC. | $329.85 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $299.42 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $235.56 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $175.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.40 | 2021-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $111.35 | 2021-2025 | Orencia, Opdualag |
| Genentech USA, INC. | $104.93 | 2019-2024 | Actemra |
| Aurinia Pharma U.S., INC. | $75.30 | 2021-2023 | Lupkynis |
| Organon LLC | $62.73 | 2024-2025 | Hadlima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $58.31 | 2022-2024 | |
| Genzyme Corporation | $56.98 | 2024-2025 | |
| Mylan Institutional INC. | $48.10 | 2023 | Hulio |
| Radius Health, INC. | $32.94 | 2023-2024 | Tymlos |
| Mallinckrodt Hospital Products INC. | $29.21 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.73 | 2025 | Purified Cortrophin Gel |
| Celltrion USA INC. | $22.24 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $21.93 | 2024 | Arcalyst |
| Celgene Corporation | $20.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eisha Mubashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.